68Ga-DOTATOC PET/CT在三种不同情境下对胰岛素瘤的作用:一项回顾性研究
该回顾性研究分析了71例成年患者,评估68Ga-DOTATOC PET/CT在散发性良性、散发性转移性和多发性内分泌腺瘤病1型(MEN1)三种情境下检测和 extent 胰岛素瘤的表现。在17例确诊散发性胰岛素瘤患者中灵敏度为75%,35例疑似患者中为39%,10例转移性胰岛素瘤随访中为100%,5例MEN1病史患者判读困难。排除MEN1病史后全局灵敏度64%(转移性100%,良性62%),特异性89%。结论认为该检查在选定情境中有用,阴性或MEN1情境下应补充GLP-1受体PET。
要点
- 确诊散发性胰岛素瘤患者中68Ga-DOTATOC PET/CT灵敏度为75%。
- 疑似胰岛素瘤患者中灵敏度为39%,转移性胰岛素瘤随访中为100%。
- 排除MEN1病史后全局灵敏度64%、特异性89%。
核心结论
- 68Ga-DOTATOC PET/CT是选定情境下评估胰岛素瘤的有用检查工具,对转移性胰岛素瘤的检测和 extent 工作up有很高性能,对散发性良性胰岛素瘤检测有高特异性。
- 当检查阴性或在MEN1情境下,应补充GLP-1受体PET完成评估。
研究设计与样本
- 回顾性分析71例成年患者数据,这些患者因疑似或确诊散发性胰岛素瘤、MEN1情境下疑似胰岛素瘤、转移性胰岛素瘤随访或疑似胰岛素瘤复发而接受68Ga-DOTATOC PET/CT。
- 以病理检查或强临床和生物学发现作为标准真相。
主要发现
- 17例确诊散发性胰岛素瘤患者中,SR-PET灵敏度为75%,包括2例SR-PET揭示了转移性病变的患者。
- 35例疑似胰岛素瘤患者中灵敏度为39%。
- 10例转移性胰岛素瘤随访患者中灵敏度为100%。
- 5例有MEN1病史患者中SR-PET判读困难,其中3例呈现多个胰腺摄取灶。
- 排除MEN1病史后所有胰岛素瘤中SR-PET全局灵敏度为64%(转移性胰岛素瘤100%,良性胰岛素瘤62%),特异性为89%。
关键数值与推荐
- 确诊散发性胰岛素瘤17例:SR-PET灵敏度75%。
- 疑似胰岛素瘤35例:灵敏度39%。
- 转移性胰岛素瘤随访10例:灵敏度100%。
- 排除MEN1病史后全局灵敏度64%(转移性100%,良性62%),特异性89%。
临床怎么用
- 作者结论认为68Ga-DOTATOC PET/CT是选定情境下评估胰岛素瘤的有用检查工具。
- 作者建议当检查阴性或在MEN1情境下应补充GLP-1受体PET。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The aim of this study was to assess the performance of 68Ga-DOTATOC PET/CT in the detection and extension of insulinomas according to 3 different contexts: sporadic benign, sporadic metastatic, and multiple endocrine neoplasia type 1 (MEN1). PATIENTS AND METHODS: The data of 71 adult patients who underwent 68Ga-DOTATOC PET/CT for suspected or confirmed sporadic insulinoma, suspicion of insulinoma in the context of MEN1, follow-up of metastatic insulinoma, or suspicion of recurrence of insulinoma were retrospectively analyzed. Pathological examination or strong clinical and biological findings were used as standards of truth. RESULTS: For the assessment of a confirmed sporadic insulinoma in 17 patients, the sensitivity of SR-PET was 75%, including 2 patients for whom metastatic lesions had been revealed by SR-PET. For 35 patients with a suspicion of insulinoma, the sensitivity was 39%. In 10 patients followed up for metastatic insulinoma, the sensitivity was 100%. For 5 patients with a history of MEN1, interpretation of SR-PET was difficult, as 3 of them presented with multiple pancreatic uptake foci. The global sensitivity of SR-PET in all insulinomas excluding those with a MEN1 story was 64% (100% for metastatic insulinomas, 62% for benign insulinomas), with a specificity of 89%. CONCLUSIONS: 68Ga-DOTATOC PET/CT is a useful examination tool for the assessment of insulinomas in selected contexts, with very high performance for the detection and extension workup of metastatic insulinomas and high specificity for the detection of sporadic benign insulinomas. The examination should be completed with GLP-1 receptor PET when it is negative or in a MEN1 context.
引用
- Moreau PL, Aveline C, Christin-Maitre S, et al. Role of 68Ga-DOTATOC PET/CT in Insulinoma According to 3 Different Contexts: A Retrospective Study. Clin Nucl Med. 2022. PMID: 35307723. doi:10.1097/RLU.0000000000004126
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。